DIAGNOS Announces the Management of the Flagship Nuevo Yo Program by Novo Nordisk

BROSSARD, Quebec, Jan. 10, 2018 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX VENTURE:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today an alliance with Novo Nordisk to monitor diabetes patients.

“At Novo Nordisk, we strive to empower the worldwide global community so they can better #knowyourrisk, by changing diabetes outcomes. We needed an accurate technology platform to match our high quality of standards to match our patient-centered Nuevo Yo program and the Diagnos solution filled the requirement that we were looking for ”, states Yiannis Mallis, Vice President & General Manager Mexico.

“We will provide the best medical support and patient attention to detect and prevent blindness by also using the measurement of their cardiovascular risk using the same retina photograph that we use for retinopathy screening”, said Dr. Hadi Chakor, Chief Medical Officer at Diagnos. “In six months we will monitor the evolution of both critical chronic diseases in 500 patients with our non-invasive AI technology: one screening at the beginning of the program and a second screening 6 months after.”

“In a changing environment like today’s, we do not only innovate in our AI engine but also finding new collaboration models with Novo Nordisk along with its strategic partner in the retail pharmacy stores. This is a three-party effort that reflects the willingness to offer the best combined specialties to the general public,” said Mr. Guillermo Moreno, Vice President Diagnos.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries.

About DIAGNOS and its technologies

DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, text and traditional data mining.  DIAGNOS has developed its own Artificial Intelligence (“AI”) technologies, CARA and FLAIREFLAIRE is a powerful AI engine that provides the capability of analyzing large and complex data sets.  Using Deep Learning methodology combined with our own proprietary algorithms we can deploy rapidly new solutions to the healthcare market

Additional information on DIAGNOS is available at www.diagnos.ca  and www.sedar.com.

For further information, please contact:             

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

Daniel Renaud or Thomas Renaud, Managing Directors
Arrowhead Business and Investment Decisions, LLC
Tel: +1 212 619 6889, ext. 7010
diagnos@arrowheadbid.com

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Left Menu Icon
Right Menu Icon